Ingredients3,3′-Diindolylmethane (abbreviated DIM) is the systematic chemical name for this compound, used consistently in the peer-reviewed scientific literature. DIM is a biologically active dimer derived from the endogenous conversion of indole-3-carbinol (I3C), a naturally occurring glucosinolate found in many cruciferous vegetables (Brassicaceae). The compound belongs to the broader class of dietary indoles and is classified as a phytochemical. Its molecular structure consists of two indole groups linked by a single methylene (–CH₂–) bridge.
DIM is a natural compound formed during the autolytic breakdown of glucobrassicin present in food plants of the Brassica genus, including broccoli, cabbage, Brussels sprouts, cauliflower and kale. The autolytic breakdown of glucobrassicin requires the catalytic reaction of the enzyme myrosinase, which is endogenous to these plants and released upon rupture of the cell wall.
Critically, DIM is not itself directly present in intact plant tissue at meaningful levels. Upon plant cell damage (i.e., chewing), inert glucosinolates are converted to indoles and isothiocyanates by myrosinase. Glucobrassicin, a predominant glucosinolate in many common Brassica vegetables, is hydrolyzed to indole-3-carbinol (I3C). When I3C is orally ingested, due to its chemical instability in acidic conditions, such as in the stomach environment, the compound is promptly condensed into DIM, which is the bioactive product. Once ingested, I3C is rapidly converted to multiple oligomers, of which DIM is the predominant active agent and the molecule responsible for the majority of the observed effects.
The anti-cancer effect of cruciferous vegetables is widely thought to be mediated by their glucosinolates, and epidemiologic evidence points to an association between high cruciferous vegetable consumption and decreased cancer risk, but the association is inconsistent, due in large part to a lack of objective measures of phytochemical exposure and uptake.
The compound is normally manufactured by chemical synthesis but may also be prepared by natural means from the extracts of Brassica vegetables, including from sprouting broccoli or from broccoli seeds. A major challenge for supplemental use is that crystalline DIM has very poor oral bioavailability. DIM is known as an agent of natural origin that provides protection against different cancers due to the broad spectrum of its biological activities in vivo; however, this substance has very poor biodistribution and absorption in animal tissues.
To address this, several enhanced-bioavailability formulations have been developed. One widely studied formulation, BioResponse-DIM® (BR-DIM), supplies DIM within a patented oral formulation containing d-alpha-tocopheryl acid succinate, phosphatidylcholine, and silica microencapsulated in starch. Typically, the diindolylmethane compound is adapted for increased bioavailability in order to reduce the required dosage. DIM is sold as a dietary supplement in capsule and tablet form, and has also been studied in vaginal suppository formulations for gynecological applications.
Traditional diets rich in cabbage, kale, and other brassicas go back centuries in European and Asian cuisines. Traditional cuisines rich in crucifers include Eastern European, Mediterranean, and South Asian dishes, such as fermented sauerkraut, kale stews, and mustard-greens saag. It is important to note that while the parent vegetables have been consumed for millennia, DIM itself was not a recognized entity in any traditional medical system. No traditional pharmacopeia — Ayurvedic, Chinese, Greek, or otherwise — named or deliberately prepared DIM as an isolated compound.
Although humans have eaten cruciferous vegetables for millennia, 3,3′-diindolylmethane itself was only recognized in the scientific community around the late 1970s and early 1980s, when researchers isolated indole-3-carbinol (I3C) as a breakdown product of glucobrassicin. DIM's discovery dates back to the 1980s when researchers investigating cancer-protective compounds in cruciferous vegetables isolated indole-3-carbinol and later DIM as its active stable form. Early studies in animal models (1984–1990) hinted at DIM's ability to influence estrogen metabolism, followed by human trials in the 2000s exploring hormone-related conditions.
The interest in isolating and supplementing DIM specifically arose from epidemiological observations that populations consuming high amounts of cruciferous vegetables appeared to have lower risks of certain cancers. Rising evidence provides credible support towards the potential role of bioactive products derived from cruciferous vegetables such as broccoli, cauliflower, kale, cabbage, Brussels sprouts, turnips, kohlrabi, bok choy, and radishes. Many epidemiological studies point out that Brassica vegetables protect humans against cancer since they are rich sources of glucosinolates in addition to possessing a high content of flavonoids, vitamins, and mineral nutrients.
I3C readily dimerizes into 3,3′-diindolylmethane (DIM), which is an acid-catalyzed stable compound and a presumed active chemopreventive agent. Because I3C is chemically unstable and rapidly converts to DIM and other oligomers in the acidic stomach environment, many researchers now focus directly on DIM as the likely primary bioactive agent when either compound is administered orally.
DIM is reported to modulate the aryl hydrocarbon receptor (AhR), as evidenced in multiple breast cancer cell lines. Aryl hydrocarbon receptor is a ubiquitous cytoplasmic receptor that, when activated and transported to the nucleus, promotes transcription of genes that stimulate the expression of detoxification enzymes, including the phase I cytochrome P450 (CYP) family. Upon binding with an agonist, conformational changes occur in AhR, prompting its translocation to the nucleus where it engages with ARNT; the resultant heterodimer complex then binds to a specific XRE and coregulators in the promoter region of AhR target genes to regulate their transcription.
Modulation of AhR by DIM treatment has also been shown to stimulate the Nrf2-mediated phase II response, which enhances excretion of genotoxins and induces a significant antioxidant response. Through the activation of AhR and Nrf2 signaling pathways, DIM effectively increases detoxification and reduces inflammatory signaling, blocking what could otherwise be cancer-initiating events.
One of the most extensively studied actions of DIM is its capacity to modulate estrogen hydroxylation. DIM's modulation of estrogen metabolism occurs through its induction of cytochrome P450 enzymes, particularly CYP1A1 and CYP3A4. Estrogen is metabolized via competing hydroxylation pathways: the 2-hydroxylation pathway produces 2-hydroxyestrone (2-OHE1), while the 16α-hydroxylation pathway produces 16α-hydroxyestrone (16α-OHE1). The 2-OHE1 metabolite is often considered "protective" or "good" estrogen because it binds weakly to estrogen receptors and does not stimulate cellular proliferation. In contrast, 16α-OHE1 is highly estrogenic and proliferative. DIM is reported to favor the 2-hydroxylation pathway, shifting the 2-OHE1:16α-OHE1 ratio in a direction considered biochemically favorable.
DIM was the first pure androgen receptor antagonist isolated from the Brassicaceae family and has been recently investigated for its potential pharmacological use in prostate cancer prevention and treatment. In preclinical prostate cancer studies, DIM modulates estrogen metabolism and acts as an anti-androgen which down-regulates the androgen receptor and prostate-specific antigen (PSA).
DIM mitigates inflammation by blocking various inflammation-inducing factors such as TNF-α, ILs, TLR, RANKL, JAK/STAT pathway, LPS, and CD40, which eventually inhibited the translocation and inhibition of NF-κB. Other potential mechanisms of action of I3C/DIM in prostate cancer include induction of apoptosis by upregulation of BAX, downregulation of Bcl-2 and BCLXL, and inactivation of Akt and NF-κB.
In cell line studies, DIM had an antiproliferative effect on both LNCaP and DU145 prostate cancer cells. FACS analysis revealed a DIM-mediated G1 cell cycle arrest. DIM strongly inhibited the expression of CDK2 and CDK4 protein and increased expression of the cell cycle inhibitor p27Kip1 protein.
In vitro, DIM has action as a histone deacetylase inhibitor, specifically against HDAC1, HDAC2, and HDAC3. HDAC inhibition can affect the epigenetic regulation of gene expression, including the reactivation of silenced tumor suppressor genes.
There is evidence that DIM can also interact with cannabinoid receptors. DIM was found to be a mild cannabinoid agonist with low binding affinity for both CB1 and CB2. In one prostate cancer cell study, in the PC3 cell line, DIM was able to activate CB2 receptors and potentially associated apoptotic pathways.
A significant nuance in DIM's pharmacology concerns its relationship with estrogen receptor alpha (ERα). At lower concentrations (10 µM), DIM has been found to induce ERα target genes such as GREB1 and TFF1 and increase cellular proliferation; these transcriptional and proliferative effects were confirmed to be mediated by ERα. In contrast, higher concentrations of DIM (e.g., 50 µM) have an opposite and expected effect on cells, which is to inhibit proliferation. This bidirectional, concentration-dependent behavior underscores the complexity of DIM's endocrine interactions and has important implications for interpreting its effects in vivo.
DIM, at physiologically relevant concentrations, not only induced human pregnane X receptor (hPXR) transactivation of CYP3A4 promoter activity but also induced gene expression of CYP3A4 and MDR1. DIM decreased intracellular accumulation of MDR1 substrate rhodamine 123, suggesting that DIM induces the functional expression of MDR1, which plays an important role in mediating adverse drug interactions.
3,3′-Diindolylmethane (DIM), a dietary AhR ligand, shifts the balance among T helper 2 (Th2)/Th17/Treg cells toward Treg cells to ameliorate colitis. This immunomodulatory capacity through AhR-mediated Treg promotion has prompted interest in inflammatory and autoimmune disease contexts, though human data remain limited.
Summary of evidence strength: Moderate — human data exist across multiple trial designs, but clinical significance of metabolite shifts remains uncertain.
DIM supplementation resulted in changes in estrogen urinary metabolites in postmenopausal women with a history of early-stage breast cancer. Both DIM and I3C may alter estrogen urinary metabolite profiles in women; however, their effects on breast cancer risk are unknown.
A 2024 study published in BMC Complementary Medicine and Therapies examined DIM's impact on the urinary estrogen profile of premenopausal women. The results of this study, taken together with the theoretical and observed partial mechanism of action of DIM, provide moderate evidence supporting the potential clinical utility of DIM and strong evidence supporting the definite clinical utility of urinary estrogen and estrogen metabolite monitoring in the setting of DIM supplementation. Additional work is needed to completely reveal how the complex mechanism of action of DIM is reflected in the complex estrogen metabolism pathway.
A 2025 retrospective study published in Menopause analyzed data from 1,458 postmenopausal women using transdermal estradiol (E2) patches. Of these women, those taking DIM had significant changes in their urinary estrogen profiles compared to those using the patch alone. DIM altered six out of ten estrogen metabolites, suggesting a potential interaction that could affect the effectiveness of menopausal hormone therapy (MHT). DIM users had significantly different urinary estrogen profiles, including lower estrone and estriol levels, and higher concentrations of 2-hydroxyestrone and 2-hydroxyestradiol.
A pilot clinical study examined the effect of 300 mg DIM/day for 14 days in patients with thyroid proliferative disease (TPD). Researchers initiated a pilot clinical study to examine the effects of oral DIM supplementation in women with TPD. The study examined the effect of oral administration of 300 mg DIM/day for 14 days and analyzed the DIM effect on estrogen metabolism by quantitating the levels of 2-OHE and 16-OHE1.
Summary of evidence strength: Preclinical evidence is substantial; human clinical evidence is limited and preliminary. No large-scale efficacy trial has confirmed a reduction in breast cancer incidence.
DIM is thought to be superior to I3C as a chemoprotective agent against breast and prostate cancers. Preclinical studies suggest DIM has anti-inflammatory, antiproliferative, and chemopreventive effects and may also help increase bone mass.
A randomized, double-blind, placebo-controlled trial enrolled women (n=130) prescribed tamoxifen who were randomly assigned to receive BioResponse-DIM® (BR-DIM) providing 150 mg DIM twice daily, or placebo, for 12 months. In participants assigned DIM, there was a significant and sustained shift in urinary estrogen metabolism favoring a higher 2-OH:16α-OH ratio; sex hormone-binding globulin (SHBG) was also increased. No change in breast density was demonstrated. However, this study also revealed a significant safety signal: safety analysis showed no appreciable differences in adverse events by treatment arm; however, tamoxifen metabolism for the parent compound as well as endoxifen and 4-OH endoxifen were appreciably reduced in women assigned to the DIM arm. This finding of reduced endoxifen — an active tamoxifen metabolite — is clinically important. This study was the first to demonstrate a decrease in serum levels of the more bioactive forms of tamoxifen, including endoxifen, findings that suggest an effect of DIM on the pharmacokinetics of tamoxifen.
It has been shown that DIM acts directly to cause apoptosis in human breast, endometrial, cervical, ovarian, prostate, and colon tumor cells in culture. These cell-line findings, while mechanistically informative, are not direct evidence of human efficacy.
The systematic review by Danciu et al. (2020), which analyzed 22 human clinical trials, found that: DIM has increased estrogen metabolism, decreased androgen-specific antigen, up-regulated BRCA1 expression, and increased androgen hormone-binding globulin. This suggests that DIM may have a promising beneficial role as a chemo-preventive supplement for breast and prostate cancers. However, the same review concluded: the absence of clinical evidence about DIM efficacy to treat prostate or breast cancer patients is the concern as this dietary compound is being advocated as a supplement in the market to treat these disease conditions. The maximum DIM intervention time for breast and prostate cancer patients was 28 days and 12 months, respectively, and most of the prospective trials were targeting DIM biological fate, rather than adequately addressing DIM efficacy in treating breast or prostate cancer.
Summary of evidence strength: Phase I human safety and pharmacokinetic data exist; preliminary signals of PSA modulation observed. No phase III efficacy data. Evidence is early-stage.
DIM was the first pure androgen receptor antagonist isolated from the Brassicaceae family and has been investigated for its potential pharmacological use in prostate cancer prevention and treatment.
A phase I dose-escalation study of oral BR-DIM was conducted in men with castrate-resistant, non-metastatic prostate cancer. Cohorts of 3–6 patients received escalating doses of twice-daily oral BR-DIM providing DIM at 75 mg, then 150 mg, 225 mg, and 300 mg, with the objective to determine the maximum tolerated dose, toxicity profile, and pharmacokinetics, and to assess effects on serum PSA and quality of life.
A separate phase Ib placebo-controlled tissue biomarker trial of BR-DIM was conducted in prostate cancer patients before prostatectomy. There was a statistically significant difference in the change in the urinary 2-hydroxyestrone/16-hydroxyestrone ratio from baseline until before surgery between the placebo and 400 mg DIM groups, with otherwise statistically nonsignificant changes in plasma biomarker expression. The administration of BR-DIM to prostate cancer patients before prostatectomy yielded detectable plasma levels but without consistent or significant tissue accumulation or biomarker modulation.
Regarding prostatic intraepithelial neoplasia (PIN), an interim safety study enrolled 14 patients randomized to 900 mg DIM or placebo daily for 3 months. The trial revealed that treatment was associated with minimal toxicity and no serious adverse events when administered orally for 3 months, with three adverse events noted, including nausea and diarrhea in two patients (14%).
Limited human data indicate daily supplementation with DIM may benefit patients with castration-resistant prostate cancer by inhibiting the androgen receptor, but studies are mixed on whether it exerts positive effects in women with cervical cell abnormalities.
Mechanistically, preclinical work has identified activation of AMPK by BR-DIM resulted in the down-regulation of AR and PSA expression, and caused induction of cell apoptosis, suppression of the mTOR pathway, and inhibition of prostasphere formation in human prostate cancer cells in vitro and in vivo. The AMPK pathway was identified as one of the novel molecular targets of BR-DIM for its anti-cancer effects against human prostate cancer.
Summary of evidence strength: One positive phase IIa RCT exists for intravaginal DIM in CIN I–II; a separate oral DIM study showed mixed results. Evidence is preliminary but includes controlled trials.
A multicenter, randomized, placebo-controlled, double-blind, parallel-group phase IIa trial enrolled 78 women of reproductive age with CIN I–II. The trial examined the efficacy and safety of a novel pharmaceutical composition in the form of vaginal suppositories containing diindolylmethane in the course of CIN I–II conservative treatment. The efficacy of active drug treatment (100 and 200 mg/day) in both treatment groups was significantly higher in comparison with the placebo group, according to the primary efficacy endpoint (proportion of patients with complete CIN regression after 90–180 days of study drug treatment). The use of diindolylmethane in the form of intravaginal suppositories was concluded to be effective in patients with CIN I–II and was not accompanied by clinically significant side effects.
By contrast, a separate clinical study using an oral preparation reported different findings, and the overall body of evidence on oral DIM for CIN shows mixed results. DIM has shown some clinical efficacy to treat cervical/prostate dysplasia, human papillomavirus, and warts. When BioResponse DIM was administered orally to HPV-16 transgenic mice, it was found to inhibit cervical dysplasia, alter estrogen metabolism, and enhance immune response.
Summary of evidence strength: Preliminary; limited clinical use reported in small studies, including in a pediatric model.
Diindolylmethane, a natural product from cruciferous vegetables, has been shown to be a dietary component that has inhibitory effects on some tumors, including laryngeal papilloma. DIM is used to treat recurrent respiratory papillomatosis. An animal safety model found that the data indicated that DIM is safe, with no significant side effects found, even with DIM at a dose 10 times higher than that currently used in practice, and it further confirmed results and safety reported from previous studies in adult humans and the adult animal model.
Summary of evidence strength: Preclinical only; no human clinical trial data yet.
A 2025 study explored DIM in the context of metabolic dysfunction-associated fatty liver disease (MAFLD). DIM significantly attenuated body weight gain and hepatic injury brought on by high-fat diet, decreased lipid droplet accumulation in HepG2 cells, and effectively suppressed the phosphorylation of p38 MAPK and the protein expression levels of fatty acid transporters CD36 and FATP4. DIM reduced lipid accumulation by activating AhR and suppressing p38 MAPK phosphorylation, thereby inhibiting fatty acid transport and inflammatory responses. These findings suggest that DIM may represent a promising therapeutic candidate for MAFLD, warranting further exploration for clinical applications. This remains entirely preclinical at this time.
Summary of evidence strength: Predominantly preclinical; mechanistic findings support interest but human data are absent.
DIM has been shown to possess hepatoprotective, antioxidant, and anticancer properties. Through AhR-mediated pathways, DIM can modulate the regulatory T-cell (Treg) response. DIM, a dietary AhR ligand, shifts the balance among Th2/Th17/Treg cells toward Treg cells to ameliorate colitis. These findings derive from animal studies and suggest potential but have not been replicated in human clinical trials.
The following dosages are reported from clinical studies only and are not recommendations:
The BioResponse formulation of DIM has been allowed unrestricted human use as a dietary supplement in the United States under the Dietary Supplement Health and Education Act of 1994. The known side effects — nausea, dyspepsia, and flatulence — are mild, reversible, and uncommon. There have been reports that DIM may increase the severity of headaches in women who get migraines.
At the 300 mg dose, one of six subjects reported mild nausea and headache, and one also reported vomiting. Only the latter effect was judged as probably related to the study agent.
DIM is considered a relatively safe substance. However, sparse evidence in the form of well-designed human clinical trials exists to test its efficacy or safety.
The most clinically significant documented interaction involves tamoxifen. In the randomized trial of DIM co-administered with tamoxifen, one clinical study showed a significant decrease in serum endoxifen. Endoxifen is an active metabolite of tamoxifen during phase I metabolism and exhibits higher affinity for the estrogen receptor. More research is needed to elucidate the pharmacokinetics and clinical efficacy of tamoxifen when taken with DIM.
DIM, at physiologically relevant concentrations, induced CYP3A4 promoter activity and gene expression of CYP3A4 and MDR1, and decreased intracellular accumulation of MDR1 substrate rhodamine 123. Caution is therefore advised when using diindolylmethane in conjunction with other medications during multidrug therapy. These enzyme interactions mean that DIM may alter the plasma levels of drugs that are substrates of CYP3A4 or that are transported by MDR1/P-glycoprotein.
DIM altered six out of ten estrogen metabolites in postmenopausal women on transdermal estradiol patches, suggesting a potential interaction that could affect the effectiveness of MHT. Healthcare providers should inquire about DIM use in patients on MHT, as it may impact treatment outcomes like symptom relief and bone health. The prescribing information for estradiol patches currently includes a warning for CYP3A4 inducers, such as St. John's wort, but does not currently mention DIM.
Because of DIM's potential hormonal effects, women who are pregnant, planning to get pregnant, or nursing should not take it. DIM is generally contraindicated during pregnancy and breastfeeding due to insufficient safety data.
Rare but serious adverse events have been documented in case reports. Memorial Sloan Kettering Cancer Center's integrative medicine database references a published case of drug rash with eosinophilia and systemic symptoms (DRESS syndrome) caused by DIM, as documented in Le TM et al., published in the Journal of Allergy and Clinical Immunology: In Practice (2016; 4(1):175–6). A case of bilateral central serous chorioretinopathy associated with DIM use was documented by Bussel et al. in Ophthalmic Surgery, Lasers and Imaging Retina (2014; 45(6):589–91). These are isolated case reports and do not establish causation, but highlight the need for post-market surveillance.
An unexpected effect of DIM on cell proliferation has been documented: stimulation of growth by inducing the ERα signaling pathway at low concentrations. Importantly, this proliferative effect occurs at potentially physiological concentrations that can be provided by the diet or by taking supplement caplets. This observation complicates the assumption that DIM is uniformly anti-estrogenic, particularly at lower supplemental doses, and underscores the need for more human dose-response research.
Results from human pharmacokinetic studies are indicative of significant phase I and phase II metabolism and differ from previous pharmacokinetic studies in rodents and humans, which had reported only parent DIM present after oral administration. One monohydroxylated metabolite exhibited greater potency and efficacy as an aryl hydrocarbon receptor agonist. Additional metabolites may exhibit pharmacological activity, highlighting the importance of further characterization of DIM metabolism in humans.
Health conditions that DIM (diindolylmethane) may help support.
DIM modulates estrogen and androgen metabolism, which may reduce hormonal drivers of acne such as excess sebum production. In vitro research published in Microbiology Spectrum (2022) demonstrates DIM inhibits Cutibacterium acnes biofilm formation. Clinical data are limited, with small studies suggesting reduced inflammatory lesions; larger RCTs are still needed.
Diindolylmethane (DIM) is a bioactive compound derived from cruciferous vegetables that modulates estrogen metabolism, shifting it toward the less potent 2-hydroxy pathway. In aging men, rising estrogen levels due to increased aromatase activity compete with declining testosterone—DIM's aromatase-modulating effect helps restore the testosterone-to-estrogen ratio. It is listed among the most prevalent individual components in testosterone booster supplements targeting andropause.
DIM activates the Nrf2 antioxidant response pathway, upregulating cytoprotective enzymes including NQO1, HO-1, and glutathione-related enzymes. A PMC-indexed mouse study showed DIM protected against CCl4-induced chronic liver injury via Nrf2 cascade activation. This antioxidant activity is preclinical; no dedicated human RCT has evaluated DIM solely for antioxidant endpoints.
Diindolylmethane (DIM), the active stomach-acid condensation product of indole-3-carbinol, has been evaluated in multiple clinical trials for CIN. A pilot RCT found 47% of CIN 2/3 subjects improved by 1–2 grades at 2 mg/kg/day. A larger double-blind RCT (n=551) showed a non-significant trend toward reduced CIN2+ progression. A phase IIa multicenter RCT using vaginal DIM suppositories also demonstrated benefit for CIN I–II.
Multiple preclinical studies show DIM suppresses key inflammatory mediators including NF-κB, TNF-α, IL-6, and IL-1β. Animal models of arthritis, autoimmune encephalomyelitis, and colonic inflammation have all shown benefit. Human clinical evidence is indirect, as inflammatory biomarkers have been monitored in cancer and prostate trials.
Diindolylmethane (DIM), formed from indole-3-carbinol during digestion of cruciferous vegetables, promotes favorable estrogen metabolism by shifting 16α-hydroxyestrone toward 2-hydroxyestrone, potentially reducing the hyperestrogenic drive of endometriosis. No clinical RCTs specifically for endometriosis have been published; evidence is preclinical and mechanistic.
DIM is a cruciferous-vegetable phytonutrient that modulates estrogen metabolism via induction of CYP1A1 and CYP1A2, shifting the 2-OHE1:16α-OHE1 ratio toward the less proliferative 2-hydroxylated pathway. A double-blind RCT (Thomson et al., Cancer Epidemiol Biomarkers Prev, 2017) showed 150 mg DIM twice daily produced a significant, sustained increase in this ratio and raised SHBG in women on tamoxifen. A 2024 large retrospective cohort (n=909 DIM users) confirmed significant alterations across the full urinary estrogen profile in premenopausal women.
Heavy periods can result from estrogen dominance; DIM shifts estrogen metabolism toward less proliferative metabolites, providing a plausible mechanism. A small RCT in women with endometriosis found that DIM 300 mg/day alongside standard treatment significantly improved bleeding patterns. No dedicated large RCT exists for heavy menstrual bleeding as the primary endpoint.
DIM is a metabolite of indole-3-carbinol from cruciferous vegetables, extensively studied for shifting estrogen metabolism toward the less estrogenic 2-hydroxylation pathway. Multiple human observational and clinical studies show DIM supplementation alters urinary estrogen metabolite profiles, increasing the favorable 2-OHE1:16-OHE1 ratio. It modulates hepatic CYP1A1, CYP1A2, and CYP3A4 enzymes central to Phase I estrogen detoxification.
DIM (Diindolylmethane) is a compound derived from indole-3-carbinol in cruciferous vegetables that modulates estrogen metabolism, shifting it toward less potent metabolites and potentially increasing free testosterone by reducing aromatase activity. ConsumerLab lists it among evaluated testosterone-support ingredients for men. Small clinical studies support its anti-estrogenic effects.
Diindolylmethane (DIM) is the primary active metabolite of indole-3-carbinol from cruciferous vegetables, acting as an Nrf2 and AhR ligand inducing hepatic phase I and II detoxification enzymes. It promotes favorable estrogen and xenobiotic metabolism in the liver. Scientific research documents its role in upregulating GST, UGT, and CYP1A-mediated hepatic biotransformation relevant to liver detox.
DIM (3,3'-diindolylmethane) is a metabolite of indole-3-carbinol formed during digestion of cruciferous vegetables. It modulates estrogen metabolism by promoting conversion of potent estrogens to weaker 2-OHE1 metabolites, which is considered beneficial during the hormonal shifts of menopause. It is a recognized menopause-related ingredient in multiple databases.
In an ovariectomized mouse model mimicking postmenopausal bone loss, DIM significantly increased bone mass by suppressing osteoclastic bone resorption. A separate study in zebrafish and MC3T3-E1 preosteoblasts confirmed DIM promotes bone formation via BAP1/IP3R/SOCE signaling. No human clinical trials on bone density outcomes have been published.
DIM has been studied in perimenopausal and postmenopausal women for its ability to alter urinary estrogen metabolite profiles, specifically increasing the 2-OHE1:16α-OHE1 ratio. A UC Berkeley human clinical trial demonstrated this shift in estrogen metabolites in women with breast cancer history. DIM is used clinically to address estrogen-dominant perimenopausal symptoms.
DIM (3,3'-diindolylmethane) is a phytonutrient formed from cruciferous vegetables that modulates estrogen metabolism, shifting breakdown toward less potent 2-hydroxy estrogen metabolites and away from more potent 16α-hydroxyestrone. By reducing the estrogen burden relative to progesterone, DIM indirectly supports progesterone balance in conditions of estrogen dominance. A 2024 retrospective cohort study (PMC, N=909 DIM users vs. 18,385 non-users) confirmed DIM significantly alters urinary estrogen metabolite profiles in premenopausal women. Clinical use includes 200 mg/day as part of estrogen-dominance and progesterone-support protocols.
DIM (3,3'-diindolylmethane) is the acid-derived dimer and bioactive product of indole-3-carbinol (I3C), acting as the first pure androgen receptor antagonist from cruciferous plants. Clinical studies of DIM supplementation before prostatectomy suggest benefit in slowing prostate cancer progression. DIM inhibits histone deacetylase activity and regulates gene expression relevant to cell cycle and proliferation in prostate cells.
Phase Ib and Phase IIa randomized double-blind placebo-controlled trials have investigated DIM (as the formulation Infemin) in men with prostatic intraepithelial neoplasia (PIN). An interim analysis in 21 patients showed a 53.3% improvement in maximal urinary flow rate and 45.5% complete PIN regression, though statistical significance was not reached due to small sample size.
DIM (3,3'-diindolylmethane) is derived from indole-3-carbinol, a compound in cruciferous vegetables. It modulates estrogen metabolism, shifting it toward less potent metabolites, which may improve the testosterone-to-estrogen ratio. Included in testosterone-supplement reviews and studied as a testosterone booster in combination products, though standalone human testosterone data are limited.
DIM has been studied in multiple RCTs for cervical intraepithelial neoplasia (CIN), a condition of uterine cervical cells. A Phase IIa multicenter RCT (n=78) showed intravaginal DIM significantly improved CIN I-II regression. In vitro research demonstrates DIM suppresses estrogen-driven proliferation and EMT in human endometrial cancer cells.
DIM is widely used by practitioners and consumers to alleviate menopausal hot flashes on the basis that it favorably shifts estrogen metabolism. No published RCT has used hot flash frequency or severity as a primary endpoint for DIM specifically. The use is extrapolated from DIM's known effects on estrogen metabolite ratios.
PCOS involves androgen excess and insulin resistance; DIM's ability to modulate androgen and estrogen metabolism provides a theoretical basis for its use. No published RCT has specifically evaluated DIM in a PCOS population. Use is supported by mechanistic reasoning and clinical extrapolation from hormonal studies.
PMS symptoms including mood changes, bloating, and breast tenderness are associated with luteal-phase estrogen-progesterone imbalance. DIM is used in integrative practice to reduce estrogen dominance thought to drive PMS. A double-blind RCT of DIM for cervical abnormalities included PMS as a monitored sub-study endpoint, providing limited formal data.
Body systems that DIM (diindolylmethane) may help support.
Go back